Neuroinflammation plays a critical role in neuronal dysfunction and death of Alzheimer’s disease (AD). ApoE4 is a major risk factor of AD, while ApoE2 is neuroprotective. Little is known about the roles of ApoE isoforms in the neuroinflammation seen in AD. Their roles and mechanisms in Aβ-induced/neuroinflammation were investigated in this study using in vivo and in vitro models. Rat astrocytes were treated with lipid-poor recombinant hApoE and/or Aβ42. Mouse astrocyte lines-expressing lipidated hApoE were treated with Aβ42 and/or vitamin D receptor (VDR) agonist, 1α,25-dihydroxyvitamin D3. Cells and media were harvested for cytokine ELISA, RNA isolated for qRT-PCR, and nuclear protein for transcription factor (TF) arrays and EMSA. hApoE-transgenic and AD mice were mated to generate hApoE2/AD and hApoE4/AD mice. Mice were euthanized at 6 months of age. Brain tissues were collected for cytokine ELISA array, Aβ ELISA, immunoblotting, and immunohistochemistry. hApoE4/AD mice had significantly higher levels of inflammatory cytokines than hApoE2/AD mice. Lipidated hApoE4 significantly promoted inflammatory gene expression induced by Aβ42 but not recombinant hApoE4 in astrocytes as compared to controls. Lipidated hApoE3 provided a certain degree of protection against Aβ42-induced inflammatory response but not recombinant hApoE3 as compared to controls. Both lipidated and recombinant hApoE2 provided protection against Aβ42-induced inflammatory response compared to controls. TF array revealed that ApoE2 strongly activated VDR in Aβ42-treated astrocytes. Application of 1α,25-dihydroxyvitamin D3 completely inhibited Aβ-induced inflammatory gene expression in hApoE4-expressing astrocytes. The results suggest that ApoE4 promotes, but ApoE2 inhibits, AD/Aβ-induced neuroinflammation via VDR signaling. Targeting VDR signaling or active form of VD3 may relieve AD neuroinflammation or/and neurodegeneration.
GraingerDJ, RecklessJ, McKilliginE (2004) Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol173, 6366–6375.
11.
LaDuMJ, ShahJA, ReardonCA, GetzGS, BuG, HuJ, GuoL, Van EldikLJ (2001) Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem Int39, 427–434.
12.
LynchJR, TangW, WangH, VitekMP, BennettER, SullivanPM, WarnerDS, LaskowitzDT (2003) APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem278, 48529–48533.
13.
Jofre-MonsenyL, LobodaA, WagnerAE, HuebbeP, Boesch-SaadatmandiC, JozkowiczA, MinihaneAM, DulakJ, RimbachG (2007) Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression. Biochem Biophys Res Commun357, 319–324.
14.
MaezawaI, Zaja-MilatovicS, MilatovicD, StephenC, SokalI, MaedaN, MontineTJ, MontineKS (2006) Apolipoprotein E isoform-dependent dendritic recovery of hippocampal neurons following activation of innate immunity. J Neuroinflammation3, 21.
15.
ColtonCA, NeedhamLK, BrownC, CookD, RasheedK, BurkeJR, StrittmatterWJ, SchmechelDE, VitekMP (2004) APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol147, 62–67.
16.
OphirG, AmariglioN, Jacob-HirschJ, ElkonR, RechaviG, MichaelsonDM (2005) Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. Neurobiol Dis20, 709–718.
17.
VitekMP, BrownCM, ColtonCA (2009) APOE genotype-specific differences in the innate immune response. Neurobiol Aging30, 1350–1360.
Ordonez-GutierrezL, AntonM, WandosellF (2015) Peripheral amyloid levels present gender differences associated with aging in AbetaPP/PS1 mice. J Alzheimers Dis44, 1063–1068.
20.
GiovanniniMG, ScaliC, ProsperiC, BellucciA, VannucchiMG, RosiS, PepeuG, CasamentiF (2002) Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: Involvement of the p38MAPK pathway. Neurobiol Dis11, 257–274.
21.
GarbergP,
BallM,
BorgN,
CecchelliR,
FenartL,
HurstRD,
LindmarkT,
MabondzoA,
NilssonJE,
RaubTJ,
StanimirovicD,
TerasakiT,
ObergJO,
OsterbergT (2005) In vitro models for the blood-brain barrier. Toxicol In Vitro19, 299–334.
22.
MorikawaM,
FryerJD,
SullivanPM,
ChristopherEA,
WahrleSE,
DeMattosRB,
O’DellMA,
FaganAM,
LashuelHA,
WalzT,
AsaiK,
HoltzmanDM (2005) Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Neurobiol Dis19, 66–76.
23.
XiongH, CallaghanD, WodzinskaJ, XuJ, PremyslovaM, LiuQY, ConnellyJ, ZhangW (2011) Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer’s disease. Neurosci Bull27, 221–232.
24.
VukicV, CallaghanD, WalkerD, LueLF, LiuQY, CouraudPO, RomeroIA, WekslerB, StanimirovicDB, ZhangW (2009) Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer’s brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis34, 95–106.
25.
BuG (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: Pathways, pathogenesis and therapy. Nat Rev Neurosci10, 333–344.
26.
ChalmersK, WilcockGK, LoveS (2003) APOE epsilon 4 influences the pathological phenotype of Alzheimer’s disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol29, 231–238.
DoreyE, ChangN, LiuQY, YangZ, ZhangW (2014) Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease. Neurosci Bull30, 317–330.
30.
Nwabuisi-HeathE, RebeckGW, LaduMJ, YuC (2014) ApoE4 delays dendritic spine formation during neuron development and accelerates loss of mature spines in vitro. ASN Neuro6, e00134.
31.
WahrleSE, JiangH, ParsadanianM, HartmanRE, BalesKR, PaulSM, HoltzmanDM (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem280, 43236–43242.
32.
Hirsch-ReinshagenV, MaiaLF, BurgessBL, BlainJF, NausKE, McIsaacSA, ParkinsonPF, ChanJY, TansleyGH, HaydenMR, PoirierJ, Van NostrandW, WellingtonCL (2005) The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem280, 43243–43256.
33.
KoldamovaR, StaufenbielM, LefterovI (2005) Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem280, 43224–43235.
Gezen-AkD, DursunE, ErtanT, HanagasiH, GurvitH, EmreM, EkerE, OzturkM, EnginF, YilmazerS (2007) Association between vitamin D receptor gene polymorphism and Alzheimer’s disease. Tohoku J Exp Med212, 275–282.
36.
Gezen-AkD, DursunE, BilgicB, HanagasiH, ErtanT, GurvitH, EmreM, EkerE, UlutinT, UysalO, YilmazerS (2012) Vitamin D receptor gene haplotype is associated with late-onset Alzheimer’s disease. Tohoku J Exp Med228, 189–196.
37.
LehmannDJ, RefsumH, WardenDR, MedwayC, WilcockGK, SmithAD (2011) The vitamin D receptor gene is associated with Alzheimer’s disease. Neurosci Lett504, 79–82.
38.
HausslerMR, HausslerCA, BartikL, WhitfieldGK, HsiehJC, SlaterS, JurutkaPW (2008) Vitamin D receptor: Molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev66, S98–112.
39.
ZhangY, LeungDY, RichersBN, LiuY, RemigioLK, RichesDW, GolevaE (2012) Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol188, 2127–2135.
40.
ZhangY, LeungDY, GolevaE (2013) Vitamin D enhances glucocorticoid action in human monocytes: Involvement of granulocyte-macrophage colony-stimulating factor and mediator complex subunit 14. J Biol Chem288, 14544–14553.
41.
ChenY, LiuW, SunT, HuangY, WangY, DebDK, YoonD, KongJ, ThadhaniR, LiYC (2013) 1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J Immunol190, 3687–3695.
42.
DursunE, Gezen-AkD, YilmazerS (2011) A novel perspective for Alzheimer’s disease: Vitamin D receptor suppression by amyloid-beta and preventing the amyloid-beta induced alterations by vitamin D in cortical neurons. J Alzheimers Dis23, 207–219.
43.
WangL, HaraK, Van BaarenJM, PriceJC, BeechamGW, GallinsPJ, WhiteheadPL, WangG, LuC, SliferMA, ZuchnerS, MartinER, MashD, HainesJL, Pericak-VanceMA, GilbertJR (2012) Vitamin D receptor and Alzheimer’s disease: A genetic and functional study. Neurobiol Aging33, 1844e1841–1849.
44.
GarcionE, SindjiL, Montero-MeneiC, AndreC, BrachetP, DarcyF (1998) Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25-dihydroxyvitamin D3. Glia22, 282–294.
45.
AnnweilerC, HerrmannFR, FantinoB, BruggB, BeauchetO (2012) Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: A pre-post pilot study. Cogn Behav Neurol25, 121–127.
46.
AnnweilerC, LlewellynDJ, BeauchetO (2013) Low serum vitamin D concentrations in Alzheimer’s disease: A systematic review and meta-analysis. J Alzheimers Dis33, 659–674.
47.
HuebbeP, NebelA, SiegertS, MoehringJ, Boesch-SaadatmandiC, MostE, PallaufJ, EgertS, MullerMJ, SchreiberS, NothlingsU, RimbachG (2011) APOE epsilon4 is associated with higher vitamin D levels in targeted replacement mice and humans. FASEB J25, 3262–3270.
48.
McKeeAC, KosikKS, KowallNW (1991) Neuritic pathology and dementia in Alzheimer’s disease. Ann Neurol30, 156–165.
49.
Fernandes de AbreuDA, EylesD, FeronF (2009) Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology34(Suppl 1), S265–S277.
50.
TaiLM, KosterKP, LuoJ, LeeSH, WangYT, CollinsNC, Ben AissaM, ThatcherGR, LaDuMJ (2014) Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem289, 30538–30555.
51.
RoszerT, Menendez-GutierrezMP, CedenillaM, RicoteM (2013) Retinoid X receptors in macrophage biology. Trends Endocrinol Metab24, 460–468.
52.
ZhuangJ, ZhangH, ZhouR, ChenL, ChenJ, ShenX (2013) Regulation of prostaglandin F2alpha against beta amyloid clearance and its inflammation induction through LXR/RXR heterodimer antagonism in microglia. Prostaglandins Other Lipid Mediat106, 45–52.
53.
TichauerJE, von BernhardiR (2012) Transforming growth factor-beta stimulates beta amyloid uptake by microglia through Smad3-dependent mechanisms. J Neurosci Res90, 1970–1980.
54.
MorinagaA, OnoK, TakasakiJ, IkedaT, HirohataM, YamadaM (2011) Effects of sex hormones on Alzheimer’s disease-associated beta-amyloid oligomer formation in vitro. Exp Neurol228, 298–302.
55.
PikeCJ, CarrollJC, RosarioER, BarronAM (2009) Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol30, 239–258.
56.
LongJ, HeP, ShenY, LiR (2012) New evidence of mitochondria dysfunction in the female Alzheimer’s disease brain: Deficiency of estrogen recetor-beta. J Alzheimers Dis30, 545–558.
57.
RazmaraA, DucklesSP, KrauseDN, ProcaccioV (2007) Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res1176, 71–81.
58.
BrownCM, ChoiE, XuQ, VitekMP, ColtonCA (2008) The APOE4 genotype alters the response of microglia and macrophages to 17beta-estradiol. Neurobiol Aging29, 1783–1794.
59.
NowakK, Lange-DohnaC, ZeitschelU, GuntherA, LuscherB, RobitzkiA, Perez-PoloR, RossnerS (2006) The transcription factor Yin Yang 1 is an activator of BACE1 expression. J Neurochem96, 1696–1707.
60.
CombsCK, JohnsonDE, KarloJC, CannadySB, LandrethGE (2000) Inflammatory mechanisms in Alzheimer’s disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci20, 558–567.
61.
HenekaMT, Reyes-IrisarriE, HullM, KummerMP (2011) Impact and Therapeutic Potential of PPARs in Alzheimer’s Disease. Curr Neuropharmacol9, 643–650.
62.
Mandrekar-ColucciS, KarloJC, LandrethGE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci32, 10117–10128.
XuJ, ChavisJA, RackeMK, DrewPD (2006) Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol176, 95–105.
65.
HenekaMT, SastreM, Dumitrescu-OzimekL, HankeA, DewachterI, KuiperiC, O’BanionK, KlockgetherT, Van LeuvenF, LandrethGE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain128, 1442–1453.
66.
BrechnerT, HockeG, GoelA, FeyGH (1991) Interleukin 6 response factor binds co-operatively at two adjacent sites in the promoter upstream region of the rat alpha 2-macroglobulin gene. Mol Biol Med8, 267–285.
BehrensMI, LendonC, RoeCM (2009) A common biological mechanism in cancer and Alzheimer’s disease?Curr Alzheimer Res6, 196–204.
71.
HooperC, MeimaridouE, TavassoliM, MelinoG, LovestoneS, KillickR (2007) p53 is upregulated in Alzheimer’s disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett418, 34–37.
72.
KimH, LeeSH, LeeMN, OhGT, ChoiKC, ChoiEY (2013) p53 regulates the transcription of the anti-inflammatory molecule developmental endothelial locus-1 (Del-1). Oncotarget4, 1976–1985.
73.
SchauerIG, ZhangJ, XingZ, GuoX, Mercado-UribeI, SoodAK, HuangP, LiuJ (2013) Interleukin-1beta promotes ovarian tumorigenesis through a p53/NF-kappaB-mediated inflammatory response in stromal fibroblasts. Neoplasia15, 409–420.
74.
BalesKR, DuY, HoltzmanD, CordellB, PaulSM (2000) Neuroinflammation and Alzheimer’s disease: Critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging21, 427-432; discussion451–423.
75.
GilmoreTD (2006) Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene25, 6680–6684.
76.
Casas-TintoS, ZhangY, Sanchez-GarciaJ, Gomez-VelazquezM, Rincon-LimasDE, Fernandez-FunezP (2011) The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Hum Mol Genet20, 2144–2160.
77.
DarbinianN, CuiJ, BasileA, Del ValleL, OtteJ, MiklossyJ, SawayaBE, AminiS, KhaliliK, GordonJ (2008) Negative regulation of AbetaPP gene expression by pur-alpha. J Alzheimers Dis15, 71–82.
78.
Gomez RavettiM, RossoOA, BerrettaR, MoscatoP (2010) Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus’ gene expression profiles in Alzheimer’s disease. PLoS One5, e10153.
79.
Jordan-SciuttoKL, DragichJM, CaltagaroneJ, HallDJ, BowserR (2000) Fetal Alz-50 clone 1 (FAC1) protein interacts with the Myc-associated zinc finger protein (ZF87/MAZ) and alters its transcriptional activity. Biochemistry39, 3206–3215.
80.
RayA, ShakyaA, KumarD, BensonMD, RayBK (2006) Inflammation-responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis. J Immunol177, 2601–2609.
